A Phase 2, Multicenter, Open-label, Single-arm Trial to Evaluate the Correlation Between Objective Response Rate and Baseline Intratumoral CD8+ Cell Density in Subjects With Unresected Stage IIIB to IVM1c Melanoma Treated with Talimogene Laherparepvec

Trial Profile

A Phase 2, Multicenter, Open-label, Single-arm Trial to Evaluate the Correlation Between Objective Response Rate and Baseline Intratumoral CD8+ Cell Density in Subjects With Unresected Stage IIIB to IVM1c Melanoma Treated with Talimogene Laherparepvec

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Talimogene laherparepvec (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms TVEC-325
  • Sponsors Amgen
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 02 Aug 2016 Planned End Date changed from 1 Dec 2018 to 1 Jun 2018.
    • 02 Aug 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top